FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
1/5/2018
0:00
NaN:NaN:NaN
The FDA announced that it is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (or MRI) concerning gadolinium remaining in patients’ bodies, including the brain, for months to years after receiving these drugs.
Report side effects involving GBCAs to FDA’s MedWatch program at www.fda.gov/medwatch.
A link to the full communication detailing specific information for health care professionals and a list of FDA approved GBCAs can be found at www.fda.gov/DrugSafety.
Released 12/19/2017
More episodes from "FDA Drug Information Updates"
Don't miss an episode of “FDA Drug Information Updates” and subscribe to it in the GetPodcast app.